Lee P Lim
Overview
Explore the profile of Lee P Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
9891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jee J, Lebow E, Yeh R, Das J, Namakydoust A, Paik P, et al.
Nat Med
. 2022 Nov;
28(11):2353-2363.
PMID: 36357680
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an...
2.
Haseltine J, Offin M, Flynn J, Zhang Z, Lebow E, Aziz K, et al.
Transl Lung Cancer Res
. 2022 Sep;
11(8):1578-1590.
PMID: 36090640
Background: Cell free DNA (cfDNA) is an exciting biomarker with applications across the cancer care continuum. Determinants of cfDNA shedding dynamics remain an active research area. We performed a detailed...
3.
Zhao Y, Murciano-Goroff Y, Xue J, Ang A, Lucas J, Mai T, et al.
Nature
. 2021 Nov;
599(7886):679-683.
PMID: 34759319
Inactive state-selective KRAS(G12C) inhibitors demonstrate a 30-40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer. The genetic basis for resistance to these first-in-class...
4.
Mondaca S, Lebow E, Namakydoust A, Razavi P, Reis-Filho J, Shen R, et al.
Lung Cancer
. 2021 Oct;
162:210.
PMID: 34625293
No abstract available.
5.
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Lawrence M, Tamen R, Martinez P, Sable-Hunt A, Addario T, Barbour P, et al.
JTO Clin Res Rep
. 2021 Sep;
2(4):100151.
PMID: 34590008
Introduction: Remote consent and enrollment offer a unique opportunity to provide rare cancer populations with access to clinical research. The genomic analysis of plasma cell-free DNA (cfDNA) permits remote characterization...
6.
Iams W, Kopparapu P, Yan Y, Muterspaugh A, Zhao Z, Chen H, et al.
JTO Clin Res Rep
. 2021 Sep;
1(2):100024.
PMID: 34589931
Introduction: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of...
7.
Mondaca S, Lebow E, Namakydoust A, Razavi P, Reis-Filho J, Shen R, et al.
Lung Cancer
. 2021 Jul;
159:66-73.
PMID: 34311346
Objectives: Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) can detect ALK fusions, though data on clinical utility of this technology in the real world is limited....
8.
Awad M, Liu S, Rybkin I, Arbour K, Dilly J, Zhu V, et al.
N Engl J Med
. 2021 Jun;
384(25):2382-2393.
PMID: 34161704
Background: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRAS). The mechanisms of acquired...
9.
Horn L, Whisenant J, Wakelee H, Reckamp K, Qiao H, Leal T, et al.
J Thorac Oncol
. 2019 Aug;
14(11):1901-1911.
PMID: 31446141
Introduction: Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of genetic alterations detected in circulating tumor...
10.
Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA
Supplee J, Milan M, Lim L, Potts K, Sholl L, Oxnard G, et al.
Lung Cancer
. 2019 Jul;
134:96-99.
PMID: 31320002
Objectives: Plasma genotyping represents an opportunity for convenient detection of clinically actionable mutations in advanced cancer patients, such has been well-documented in non-small cell lung cancer (NSCLC). Oncogenic gene fusions...